En studie för att testa om behandling med BI 770371 i kombination med pembrolizumab med eller utan cetuximab hjälper människor med huvud- och nackcancer jämfört med pembrolizumab ensam
En fas IB öppen etikett randomiserad klinisk prövning för att utvärdera säkerhet och effekt av BI 770371 i kombination med pembrolizumab med eller utan cetuximab jämfört med pembrolizumab monoterapi för den första linjen av patienter med metastaserande eller återkommande huvud- och halskamouscellkarcinom (HNSCC)
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing.
Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site.
Participants can stay in the study as long as they benefit from treatment. Doctors regularly check the size of the tumor and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New South Wales
-
Gosford, New South Wales, Australien, 2250
- Gosford Hospital
-
-
Victoria
-
Geelong, Victoria, Australien, 3220
- Andrew Love Cancer Centre
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Hospital de Amor
-
Natal, Brasilien, 59062-000
- Liga Norte Riograndense contra o cancer
-
São José do Rio Preto, Brasilien, 15090-000
- Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto
-
-
-
-
-
Sofia, Bulgarien, 1404
- MBAL Sveta Sofia
-
-
-
-
-
Lille, Frankrike, 59020
- CTR Oscar Lambret
-
Lyon, Frankrike, 69373
- CTR Leon Berard
-
Marseille, Frankrike, 13385
- HOP Timone
-
Villejuif, Frankrike, 94805
- Institut Gustave Roussy
-
-
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40202
- Norton Cancer Institute, Downtown
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- M Health Fairview Clinics and Surgery Center - Minneapolis
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- The Ohio State University Wexner Medical Center
-
-
-
-
-
Tbilisi, Georgien, 0112
- ARENSIA Exploratory Medicine LLC
-
-
-
-
-
Meldola (FC), Italien, 47014
- Istituto Scientifico Romagnolo
-
Verona, Italien, 37126
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Hokkaido, Sapporo, Japan, 060-8648
- Hokkaido University Hospital
-
Hyogo, Kobe, Japan, 650-0017
- Kobe University Hospital
-
Osaka, Hirakata, Japan, 573-1191
- Kansai Medical University Hospital
-
Shizuoka, Sunto-gun, Japan, 411-8777
- Shizuoka Cancer Center
-
Tokyo, Koto-ku, Japan, 135-8550
- Japanese Foundation for Cancer Research
-
-
-
-
-
Mexico City, Mexiko, 04660
- Unidad Clinica Farmacologica Bioemagno
-
México, Mexiko, 14080
- Instituto Nacional de Cancerologia
-
México, Mexiko, 06760
- Centro Oncologico Personalizado
-
Tlajomulco de Zuñiga, Mexiko, 45640
- Centro Oncológico Internacional
-
-
-
-
-
Chisinau, Mögel, MD-2025
- ARENSIA Exploratory Medicine
-
-
-
-
-
Lublin, Polen, 20090
- Center of Oncology of the Lublin Region St. Jana z Dukli
-
-
-
-
-
Bucharest, Rumänien, 022328
- "Prof. Dr. Alexandru Trestioreanu" Oncology Institut
-
-
-
-
-
Aarau, Schweiz, 5001
- Cantonspital Aarau
-
-
-
-
-
Singapore, Singapore, 119228
- National University Hospital-Singapore-22806
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitari Vall d'Hebron
-
-
-
-
-
London, Storbritannien, EC1A 7BE
- St Bartholomew's Hospital
-
London, Storbritannien, SW3 6JJ
- The Royal Marsden Hospital, Chelsea
-
Sutton, Storbritannien, SM2 5PT
- The Royal Marsden Hospital, Sutton
-
-
-
-
-
Seoul, Sydkorea, 03722
- Severance Hospital
-
Seoul, Sydkorea, 135-710
- Samsung Medical Center
-
Suwon, Sydkorea, 16247
- The Catholic University of Korea, St.Vincent's Hospital
-
-
-
-
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10048
- National Taiwan University Hospital
-
-
-
-
-
Bangkoknoi, Thailand, 10700
- Siriraj Hospital
-
-
-
-
-
Adana, Turkiet (Türkiye), 01220
- Adana City Hospital
-
Ankara, Turkiet (Türkiye), 06800
- Ankara Bilkent City Hospital
-
Ankara, Turkiet (Türkiye), 06200
- Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turkiet (Türkiye), 06230
- Hacettepe University Oncology Hospital
-
Istanbul, Turkiet (Türkiye), 34093
- Istanbul University Medical Faculty Capa Hospital
-
-
-
-
-
Braunschweig, Tyskland, 38114
- Städtisches Klinikum Braunschweig gGmbH
-
Jena, Tyskland, 07743
- Universitätsklinikum Jena
-
Leipzig, Tyskland, 04103
- Universität Leipzig
-
Ulm, Tyskland, 89081
- Universitätsklinikum Ulm
-
-
-
-
-
Budapest, Ungern, 1083
- Semmelweis University
-
Gyöngyös, Ungern, 3200
- Clinexpert Gyongyos
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients with histologically confirmed metastatic or recurrent HNSCC of the primary tumour location of oral cavity, oropharynx, hypopharynx, and larynx not amenable to locoregional treatment with curative intent.
- Willingness to provide pretreatment (baseline) biopsy/tissue to the sponsor (fresh or archival one). A newly obtained biopsy is preferred but an archival sample is acceptable, with tumor tissue (formalin fixed paraffin embedded [FFPE] block preferred, or at least 10 freshly sectioned unstained FFPE slides) from a core or excisional biopsy. Any deviation from this rule requires approval by the sponsor. Details on the requirements for archival tumour tissue and on biopsy sample collection are provided in the Laboratory Manual.
- Patients who have not received prior systemic treatment for metastatic or recurrent HNSCC. Systemic therapy (including cetuximab) which was completed more than 6 months prior to progression of disease if given as part of multimodal treatment for locally advanced disease is allowed.
- Patients who do not have contraindications to pembrolizumab monotherapy according to pembrolizumab local label, guidelines, treatment standards, regulations or the document (label of another country if pembrolizumab local label is not available) provided in the investigator site file (ISF) by the sponsor.
- Patients who do not have contraindications to treatment with cetuximab according to cetuximab local label, guidelines, treatment standards, regulations, or the document (label of another country if cetuximab local label is not available) provided in the ISF by the sponsor.
- Presence of at least one measurable non-central nervous system (CNS) lesion (according to RECIST v1.1.).
- Further inclusion criteria apply.
Exclusion Criteria:
- Nasopharyngeal carcinoma (NPC) of any histology, primary tumour location at nasal cavity, paranasal sinuses of any histology, any cancer of unknown primary.
- Any tumour location necessitating an urgent therapeutic intervention (e.g., palliative care, surgery, or radiation therapy), such as spinal cord compression, other compressive mass, uncontrolled painful lesion, bone fracture.
- Patients with progressive HNSCC within 6 months of completion of systemic therapy for locoregionally advanced disease with curative intent.
- Receiving treatment for brain metastases or leptomeningeal disease (LMD) which may interfere with safety and/or endpoint assessment. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to trial entry, have discontinued corticosteroid treatment for these metastases and are clinically stable, off anticonvulsants for at least 4 weeks and are neurologically stable before enrollment.
- Patients for whom single agent pembrolizumab is not the preferred treatment (e.g. patients for whom chemotherapy or anti-PD-1 in combination with chemotherapy is considered the preferred therapy by the investigator or treating physician).
- Prior treatment with any anti signal regulatory protein alpha (SIRPα) or anti-integrin-associated protein (CD47) agent, regardless of treatment intent.
- Prior cancer treatment with any anti PD-1 or anti PD-L1 agent or with an agent directed to another stimulatory or co-inhibitory Tcell receptor (e.g. CTLA-4, OX 40, CD137), regardless of treatment intent.
- Prior allogeneic stem cell or solid organ transplantation.
- Further exclusion criteria apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Pembrolizumab
|
Pembrolizumab |
|
Experimentell: Pembrolizumab + bi 770371
|
Pembrolizumab BI 770371 |
|
Experimentell: Pembrolizumab + bi 770371 + cetuximab
|
Pembrolizumab BI 770371 Cetuximab |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Objective response (OR) with confirmation
Tidsram: Up to 27 months
|
OR defined as the best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to response evaluation criteria in solid tumours version 1.1 (RECIST v1.1). Objective response (OR) will be defined by investigator's assessment from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, lost to follow-up or withdrawal of consent. |
Up to 27 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Förekomst av behandlingsrelaterad biverkning (AE) från First Treatment Administration till den tidigaste av 90 dagar efter den sista dosen, döden, efterföljande anti-cancerterapi, förlorade efter uppföljning eller tillbakadragande av samtycke
Tidsram: Upp till 27 månader
|
Upp till 27 månader
|
|
|
Förekomst av behandlingsrelaterade AE som ledde till behandlingsavbrott från första behandlingsadministrationen fram till det tidigaste av 90 dagar efter den sista dosen, döden, efterföljande anti-cancerterapi, förlorade efter uppföljning eller tillbakadragande av samtycke
Tidsram: Upp till 27 månader
|
Upp till 27 månader
|
|
|
Overall survival (OS)
Tidsram: Up to 27 months
|
OS defined as the time from first treatment administration until death from any cause. |
Up to 27 months
|
|
Overall survival at 6 and 12 months (OS6 and OS12)
Tidsram: At 6 months and 12 months
|
OS defined as being alive at 6 months or at 12 months from first treatment administration. |
At 6 months and 12 months
|
|
Progression-free survival (PFS)
Tidsram: Up to 27 months
|
PFS defined as the time from first treatment administration until disease progression (PD) according to RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to 27 months
|
|
Progression-free survival at 6 months (PFS6)
Tidsram: At 6 months
|
PFS defined as being alive and without progression at 6 months from first treatment administration. |
At 6 months
|
|
Duration of objective response (DOR)
Tidsram: Up to 27 months
|
DOR defined as the time from first documented CR or PR (RECIST v1.1) until the earliest of PD or death among patients with OR. |
Up to 27 months
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer i huvud och hals
- Neoplasmer, körtel och epitel
- Carcinom
- Karcinom, skivepitel
- Skivepitelcancer i huvud och hals
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Cetuximab
- pembrolizumab
Andra studie-ID-nummer
- 1501-0002
- U1111-1312-0435 (Registeridentifierare: WHO International Clinical Trials Registry Platform (ICTRP))
- 2024-517091-38-00 (Registeridentifierare: CTIS (EU))
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Tidsram för IPD-delning
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Kriterier för IPD Sharing Access
For study documents -upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .